Scholarlink

<p>Investigate intraocular fluid testing’s role in ARNs management and prognosis. 46 ARNs patients (49 eyes) treated from 2021 to 2023 were divided into precision (<i>n</i> = 22) and conventional (<i>n</i> = 24) groups based on intraocular fluid testing. Precision group received intravitreal ganciclovir (20&#xa0;mg/ml [viral copies &lt; 5 × 10<sup>6</sup>] or 40&#xa0;mg/ml [&gt; 5 × 10<sup>6</sup>]) twice weekly; conventional group received fixed 20&#xa0;mg/ml. BCVA, viral copies, cytokines (IL-6, IL-8, IL-10), and biomarkers (VCAM, VEGF, BFGF) were analyzed. No baseline differences in BCVA, IOP, or clinical features between groups (<i>P</i> &gt; 0.05). Precision group showed fewer injections, higher final BCVA, and lower retinal detachment rates (<i>P</i> &lt; 0.05). Viral copies negatively correlated with final BCVA (<i>P</i> &lt; 0.05). In precision group: viral copies positively correlated with injection frequency, IL-6, IL-8, VCAM, BFGF; retinal necrosis extent positively linked to initial/final BCVA but inversely with IL-6, IL-8, and viral load. Conventional group showed retinal necrosis involvement positively correlated with detachment risk (<i>P</i> &lt; 0.05). Intraocular fluid testing optimizes ARNs treatment personalization, improves outcomes, and enhances prognostic evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月23日

查看全文
  • Xiao Yu,
  • Ziqing mao,
  • Yuling Zou,
  • Yao Zhao,
  • Huimin Fan,
  • Teng Liu,
  • Yiming Lei,
  • Hua Zou,
  • Zhipeng You

摘要

Investigate intraocular fluid testing’s role in ARNs management and prognosis. 46 ARNs patients (49 eyes) treated from 2021 to 2023 were divided into precision (n = 22) and conventional (n = 24) groups based on intraocular fluid testing. Precision group received intravitreal ganciclovir (20 mg/ml [viral copies < 5 × 106] or 40 mg/ml [> 5 × 106]) twice weekly; conventional group received fixed 20 mg/ml. BCVA, viral copies, cytokines (IL-6, IL-8, IL-10), and biomarkers (VCAM, VEGF, BFGF) were analyzed. No baseline differences in BCVA, IOP, or clinical features between groups (P > 0.05). Precision group showed fewer injections, higher final BCVA, and lower retinal detachment rates (P < 0.05). Viral copies negatively correlated with final BCVA (P < 0.05). In precision group: viral copies positively correlated with injection frequency, IL-6, IL-8, VCAM, BFGF; retinal necrosis extent positively linked to initial/final BCVA but inversely with IL-6, IL-8, and viral load. Conventional group showed retinal necrosis involvement positively correlated with detachment risk (P < 0.05). Intraocular fluid testing optimizes ARNs treatment personalization, improves outcomes, and enhances prognostic evaluation.